Digital Cognitive Test Catches 80% of Dementia Cases Missed by Traditional Paper Screening

A Florida-based Medicare Advantage provider has reported identifying over 90% of new dementia cases at early or mild stages within seven months of switching from traditional paper-based screening to a digital cognitive assessment platform—a finding that highlights significant gaps in conventional dementia detection methods used across primary care.

Claremedica, which serves more than 34,000 Medicare Advantage patients across 35+ Florida sites, replaced the widely-used Mini-Mental State Exam (MMSE) with Creyos digital cognitive assessment, an FDA Class II-registered platform that provides domain-level cognitive profiling rather than simple pass/fail results. The organization's dementia identification rate more than doubled following implementation, according to the report.

Traditional Screening Missed Majority of Early Cases

Perhaps most striking: nearly 80% of newly identified dementia patients had been previously screened with MMSE—in some cases multiple times—without detection. The finding suggests that conventional paper-based cognitive screeners may systematically fail to identify early-stage impairment in primary care settings, where more than 60% of cognitive impairment nationally goes unrecognized.

The shift from 12-minute MMSE assessments to 6-minute Creyos testing freed approximately 90 minutes daily per physician while simultaneously improving detection rates, the report notes. The platform achieved 95%+ physician adoption on day one, representing the highest first-day uptake across 10 clinical technology rollouts in Claremedica's disease-detection program.

Dr. Nehal Gheewala, Chief Medical Officer at Claremedica, attributed the rapid adoption to an organization-wide operational pause for staff education led by Professor Adrian Owen, Co-founder and Chief Scientific Officer of Creyos, before the first patient screening.

Value-Based Care Implications

The deployment comes as value-based care organizations face mounting pressure to manage Alzheimer's costs proactively. Current Alzheimer's prevalence stands at 7 million Americans, projected to reach 13 million by 2050. Early identification at mild stages enables proactive care planning when interventions remain most effective, potentially reducing downstream adverse events including falls and avoidable hospitalizations.

Creyos, formerly Cambridge Brain Sciences, has been validated in 400+ peer-reviewed studies and integrates with 90+ electronic health record systems including Epic and athenahealth. The platform supports 13 languages including Haitian Creole and provides structured data output designed for primary care workflows.

Tracking Long-Term Outcomes

Claremedica is now monitoring correlations between early dementia detection and falls, avoidable hospitalizations, and total cost of care over 12-24 months. The organization's experience positions digital cognitive screening as a potential infrastructure component for Medicare Advantage providers, where early chronic disease detection directly impacts reimbursement models.

The case establishes a benchmark for digital cognitive screening adoption in value-based care settings and suggests that domain-level cognitive assessment may be transitioning from clinical differentiator to standard-of-care requirement as traditional paper screeners demonstrate limitations in real-world primary care deployment.

Sources

1. Claremedica's digital test finds 90% of new dementia cases early — Longevity.Technology